TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07513623: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

Sponsor: University of California, San Francisco · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 117 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$970,200

Rescue Site Savings

+$646,800

Unlock Full NCT07513623 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07513623 Rescue Dossier →